Huan H B, Chen X J, Xia F
Department of Hepatobiliary and Pancreatic Surgery, First Medical Center of Chinese PLA General Hospital, Beijing 100048, China.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhonghua Gan Zang Bing Za Zhi. 2020 Nov 20;28(11):910-914. doi: 10.3760/cma.j.cn501113-20201029-00585.
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in China. Currently, hepatectomy, radiofrequency ablation, interventional therapy, and so on are widely used in the treatment of liver cancer; however the 5-year survival rate of patients is still very poor. The onset of liver cancer is insidious, and most patients do not have the opportunity to undergo surgery when they are initially diagnosed. In addition, patients with advanced liver cancer lack effective treatment, which is mainly due to chronic inflammation of the liver. Immunotherapy has great potential advantages in the treatment of liver cancer, so it has attracted more and more researchers' attention. Importantly, with the development of biomedical science into the era of precision medicine, more precise and effective immunotherapy strategies for HCC treatment have been explored, thus bringing new hope to HCC patients. This article reviews the research status and progress of liver cancer immunotherapy in the context of precision medicine.
肝细胞癌(HCC)是中国最常见的恶性肿瘤之一。目前,肝切除术、射频消融、介入治疗等在肝癌治疗中被广泛应用;然而,患者的5年生存率仍然很低。肝癌起病隐匿,大多数患者在初诊时没有机会接受手术。此外,晚期肝癌患者缺乏有效的治疗方法,这主要是由于肝脏慢性炎症所致。免疫疗法在肝癌治疗中具有巨大的潜在优势,因此越来越受到研究人员的关注。重要的是,随着生物医学科学进入精准医学时代,人们探索了更精确、有效的肝癌免疫治疗策略,从而为肝癌患者带来了新的希望。本文综述了精准医学背景下肝癌免疫治疗的研究现状与进展。